60%Confidence
0Views
SEC EDGARSource
2026-03-04Date
Summary
TScan Therapeutics filed an 8-K, likely covering material events in its immuno-oncology pipeline. This could include clinical trial outcomes, regulatory interactions, or strategic alliances influencing its valuation.
Actionable: Analyze the filing for updates on clinical data or partnerships that may impact investment theses in biotech.
AI Confidence: 60%
Data Points
companyTScan Therapeutics, Inc. (TCRX) (CIK 0001783328)
form8-K
date2026-03-04
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now